Advisor and Founder

Chief Commercial Officer

Regulatory actions for June 6, 2025

EC approves Santen’s Ryjunea to slow progression of pediatric myopia

EC approves Santen’s Ryjunea to slow progression of paediatric myopia

Sydnexis Announces European Commission Approval of SYD-101, the First and Only Pharmaceutical Treatment for Slowing the Progression of Pediatric Myopia

Senior Director Compliance

Sydnexis Inc. is a clinical-stage biopharmaceutical company focused on developing innovative solutions for pediatric eye health. The Senior Director of Compliance will oversee compliance initiatives, ensuring adherence to regulatory standards as the company prepares for its first potential commercial launch, while collaborating with various functions to mitigate compliance risks.

Sign up with Google

Sign in with Google